Here’s the thing: it wasn’t about the drug itself, not really. The heart of the matter, the very axis on which this protracted legal battle spun, boiled down to a number. Specifically, a pH level. Actelion, the patent holder for the hypertension drug Veletri®, sued Mylan Pharmaceuticals, alleging their generic competitor infringed upon U.S. Patent Nos. 8,318,802 and 8,598,227. The crux of Actelion’s argument hinged on the phrase “formed from a bulk solution having a pH of 13 or higher.” Simple enough on the surface, right? Wrong.
The U.S. Court of Appeals for the Federal Circuit (CAFC) just affirmed a district court decision, effectively telling Actelion that their very specific definition of “13 or higher” wasn’t going to cut it against Mylan’s generic. This isn’t just another IP squabble; it’s a masterclass in how even seemingly straightforward scientific terms can become battlegrounds when billions are on the line.
The initial district court punted, construing the claims to mean a pH of 12.5 or higher, thanks to some aggressive rounding rules. But the CAFC, in a move that signaled this was far from over, remanded the case in 2023, stating that a proper claim construction couldn’t be reached “without the aid of extrinsic evidence.” Translation: the patent language alone wasn’t enough; they needed outside expert opinion to decipher what “13 or higher” truly meant.
On remand, the district court sharpened its focus, settling on a pH of 12.98 or higher. Mylan, critically, admitted their bulk solution sat comfortably below this revised threshold. Actelion, however, threw a curveball: they argued that if measured at refrigerated temperatures, as their manufacturing process indicated, the pH would indeed exceed 13. It’s a clever bit of scientific jujitsu, trying to twist the conditions of measurement to fit their claim.
Then came the doctrine of equivalents. Actelion’s secondary argument: Mylan’s process performed the “same function” (improved manufacturing stability), achieved the “same result” (composition stability), and did so in the “same way” (reducing hydrogen ion concentration) as their patented invention. This is the patent lawyer’s Hail Mary, a way to catch infringement even if the literal wording of the patent isn’t met.
But the CAFC, in an opinion penned by Judge Taranto, shut that down too. They agreed the district court had properly construed the pH claim phrase and found no reversible error. The court meticulously dissected the intrinsic evidence – the patent’s specification and prosecution history – finding it insufficient to support Actelion’s broad interpretation. Even the examiner’s statements and the supposed purpose of the invention didn’t bolster Actelion’s case.
And the extrinsic evidence? The USP, textbooks, expert declarations – all pointed to a fundamental principle: when referring to pH in pharmaceutical compositions, the standard is standard temperature, unless explicitly stated otherwise. The CAFC saw no clear error in how the district court handled this deluge of external information.
Beyond the pH, the claim of infringement by equivalents hit a brick wall due to claim amendments made during prosecution. Actelion had narrowed its claims, and the CAFC held this created an estoppel, preventing them from later arguing that the now-abandoned, broader subject matter was simply an equivalent. They couldn’t backtrack and claim coverage they’d previously surrendered.
Even the “disclosure-dedication rule” independently barred Actelion’s equivalents theory. This rule essentially states that if you disclose something in your patent, even if you don’t claim it, you’re considered to have dedicated it to the public. Actelion’s attempt to argue that their disclosed alternative pH ranges weren’t mutually exclusive was a non-starter. It’s a clear win for Mylan, and a stark reminder of the precision required in patent drafting and litigation.
The pH Scale and Patent Peril
The core of the dispute wasn’t about whether Mylan’s drug was dangerous or ineffective – it wasn’t. It was about the meticulous, often maddening, definition of terms within a patent claim. Actelion’s attempt to use a refrigerated pH reading against a claim implicitly tied to standard conditions demonstrates a fundamental misunderstanding of how patent law grapples with scientific measurement. The CAFC’s decision underscores that ambiguity in scientific claims, especially when challenged with extrinsic evidence, often favors the party pushing for generic entry. This isn’t just about hypertension drugs; it’s about the architectural integrity of patent claims themselves, and how easily they can crumble under the weight of precise, externally validated scientific understanding.
Why Does This pH Ruling Matter for Generic Drug Makers?
This CAFC decision is more than just a footnote in patent law; it’s a beacon for generic drug manufacturers. It reinforces the principle that patents must be clearly and precisely defined, especially when they rely on quantifiable scientific parameters like pH. For generic companies, this means a greater emphasis on dissecting the scientific evidence and definitions used in patent claims. If a patent’s language is ambiguous or relies on unstated assumptions (like temperature), and if extrinsic evidence supports a different interpretation, there’s a strong defense against infringement claims. This ruling could embolden more challenges to patents that lack such scientific rigor, potentially speeding up the availability of more affordable medications.
Actelion’s attempt to stretch the definition of “13 or higher” to encompass a measurement taken under specific, unstated conditions demonstrates a common, yet often fatal, flaw in patent assertion: overreach. The court’s reliance on extrinsic evidence—standard scientific texts and expert testimony—signals that patent claims aren’t ivory towers of self-definition. They exist within a broader scientific context, and that context can, and often will, be used to interpret their scope.
The CAFC explicitly stated that the claim language alone didn’t resolve the pH question. This isn’t an uncommon scenario. Patents, especially older ones or those drafted without exhaustive foresight into every conceivable scientific nuance, can contain ambiguities. What’s fascinating here is how readily the court turned to external, objective sources to settle the matter, rather than deferring solely to the patent holder’s interpretation.
The CAFC held that the district court properly found it showed “that those skilled in making pharmaceutical compositions, when referring to pH, mean a measurement at standard temperature unless they indicate otherwise, and we discern no clear error in how the district court evaluated the record.”
This is the nail in the coffin for Actelion’s argument. The court isn’t just saying Actelion is wrong; they’re saying the established practice in the relevant scientific field dictates a different understanding, and that understanding is what matters. It’s a powerful validation of industry standards over potentially self-serving patent interpretations.
Furthermore, the estoppel doctrine, a direct result of Actelion narrowing its claims during the patent prosecution process, is a crucial takeaway. This is the legal equivalent of a trapdoor: you can’t broaden your claims later by arguing for equivalents of what you explicitly gave up. It’s a procedural safeguard against patentees trying to “reclaim” territory they abandoned to get their patent granted in the first place.
🧬 Related Insights
- Read more: Firmware Rewrites Defeat ITC Orders: A New Arms Race?
- Read more: AI Audit Frameworks: How to Assess and Document AI System Compliance
Frequently Asked Questions
What does ‘pH of 13 or higher’ mean in this legal context? In this specific CAFC ruling, the court ultimately agreed with the interpretation that ‘pH of 13 or higher’ refers to a measurement taken at standard temperature, not under refrigerated conditions, unless otherwise explicitly stated in the patent claim. Expert testimony and scientific literature supported this standard interpretation.
Will this ruling affect other drug patents? This decision sets a precedent for how scientific terms and measurements in patent claims are interpreted. It emphasizes the importance of precise language and the relevance of industry standards and extrinsic scientific evidence. Generic manufacturers may use this as a basis to challenge patents with similar ambiguities in scientific definitions.
Did Mylan’s drug actually have a pH above 13 when refrigerated? Mylan’s bulk solution had a pH well below the court-established threshold of 12.98 at standard temperature. Actelion argued that if measured while refrigerated, the pH would exceed 13, but the court found this condition was not specified in the patent claim and thus didn’t constitute infringement.
